Nyrada Inc. (NYRADA CDI FORUS [NYR]) Aktie

Nyrada Inc., a pre-clinical stage drug development company, engages in the development of small molecule drugs for cardiovascular and neurological diseases. Its lead candidate is Xolatryp, a small molecule drug which has completed phase 1 clinical trial for neuroprotection and cardioprotection indications and in patients with traumatic brain injury and ischaemic stroke. Nyrada Inc. was incorporated in 2017 and is based in Sydney, Australia.